Krystal Biotech Inc logo

Krystal Biotech Inc

KRYS
Healthcare|Biotechnology|USA
$365.80
-5.27 (-1.42%)
DCF (FCF)
$31.98
Tangible Book
$43.37
Graham Number
$85.44
Earnings Power
$26.08

Upcoming Data Readouts (9)

Dec 2026
Est. completion
P1Cystic Fibrosis
A Study Assessing KB407 for the Treatment of Cystic Fibrosis
NCT05504837n=20
Dec 2026
Est. completion
P1P2Neurotrophic Keratitis
A Study Comparing KB801 Verse Placebo in Patients With Stage 2 or 3 Neurotrophic Keratitis
NCT06999733n=60
Dec 2026
Est. completion
P3Dystrophic Epidermolysis Bullosa
A Study Comparing KB803 and Matched Placebo in Patients With Dystrophic Epidermolysis Bullosa
NCT07016750n=16
Feb 2027
Est. completion
P1P2Lung Cancer, Non-small Cell
A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs
NCT06228326n=250
Jul 2027
Est. completion
P1P2Cancer
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
NCT05970497n=240
May 2028
Est. completion
Dystrophic Epidermolysis Bullosa
Long-Term Follow-up Protocol
NCT04917887n=50
Dec 2028
Est. completion
NASchizophrenia
Cerebellar Stimulation and Cognitive Control
NCT03217110n=200
Jun 2030
Est. completion
NAMajor Depressive Disorder
Closed-Loop Deep Brain Stimulation for Major Depression
NCT04004169n=12
Jun 2030
Est. completion
NABipolar II Disorder
Closed-Loop Deep Brain Stimulation for Treatment-Resistant Bipolar Depression
NCT07127913n=10

Awaiting Results (2)

Trials past primary completion date but still active — data readout may be imminent.

Jul 2025
P1P2
A Study Assessing KB304 for the Treatment of Wrinkles in Women
NCT06724900
Oct 2024
P1
A Phase I Study of KB301, a Replication-Incompetent, Non-Integrating Vector Expressing Human Type III Collagen (COL3) for the Treatment of Superficial Skin Depressions
NCT04540900

Recent Press Releases